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Abstract
Background: Esophageal squamous cell carcinoma (ESCC), the predominant histological subtype of esophageal
cancer, is characterized by high mortality. Previous work identified important mRNA expression differences
between normal and tumor cells; however, to date there are limited ex vivo studies examining expression changes
occurring during normal esophageal squamous cell differentiation versus those associated with tumorigenesis. In
this study, we used a unique tissue microdissection strategy and microarrays to measure gene expression profiles
associated with cell differentiation versus tumorigenesis in twelve cases of patient-matched normal basal squamous
epithelial cells (NB), normal differentiated squamous epithelium (ND), and squamous cell cancer. Class comparison
and pathway analysis were used to compare NB versus tumor in a search for unique therapeutic targets.
Results: As a first step towards this goal, gene expression profiles and pathways were evaluated. Overall, ND
expression patterns were markedly different from NB and tumor; whereas, tumor and NB were more closely
related. Tumor showed a general decrease in differentially expressed genes relative to NB as opposed to ND that
exhibited the opposite trend. FSH and IgG networks were most highly dysregulated in normal differentiation and
tumorigenesis, respectively. DNA repair pathways were generally elevated in NB and tumor relative to ND
indicating involvement in both normal and pathological growth. PDGF signaling pathway and 12 individual genes
unique to the tumor/NB comparison were identified as therapeutic targets, and 10 associated ESCC gene-drug
pairs were identified. We further examined the protein expression level and the distribution patterns of four genes:
ODC1, POSTN, ASPA and IGF2BP3. Ultimately, three genes (ODC1, POSTN, ASPA) were verified to be dysregulated
in the same pattern at both the mRNA and protein levels.
Conclusions: These data reveal insight into genes and molecular pathways mediating ESCC development and
provide information potentially useful in designing novel therapeutic interventions for this tumor type.
Background
Esophageal cancer (EC) is the eighth most common can-
cer in the world and has the sixth highest mortality
[1,2]. As the predominant histological subtype of eso-
phageal cancer, esophageal squamous cell carcinoma
(ESCC) comprises 80% of all esophageal cancer world-
wide. Despite advances in diagnostic methods and
combined treatment modalities, the majority of tumors
are diagnosed at advanced stages and the overall 5-year
survival rate (1999 to 2005) is only 19% [3]. In contrast,
the 1% of patients who are diagnosed with Stage I dis-
ease (T1N0M0), invading only the lamina propria or
submucosa without lymph node or distant metastasis,
have a favorable 90% 5-year survival after resection [4].
Therefore, early diagnosis of ESCC is important in pre-
venting this cancer, and there is a significant need to
develop novel therapeutic agents for patients with
advanced disease. Moreover, ESCC shares many pheno-
typic and molecular characteristics with both squamous
cell carcinoma of the head and neck, and of the lung,
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thus new molecular insights or drug targets discovered
by studying ESCC may have widespread utility for redu-
cing cancer morbidity and mortality.
The normal esophagus is lined by a stratified squa-
mous epithelium composed of three main layers: super-
ficial, differentiated, and basal [8]. The epithelial basal
cells are adjacent to the basement membrane, are cuboi-
dal or polyhedral in shape, and comprise a layer that is
one to four cells thick and accounts for 15% or less of
the epithelium [9]. The basal layer contains proliferating
stem cells and transit-amplifying cells that migrate
towards the luminal surface during normal maturation
of the esophageal epithelium [10,11]. However, in early
squamous cell cancer formation an atypical proliferation
of the basal cell compartment is observed, initially con-
fined to the lower part of the epithelium then increas-
ingly extending through the entire epithelium [12]. Over
time the proliferating cells occupy the full thickness of
the epithelium and ultimately invade through the lamina
propria into the surrounding sub-epithelial tissue. Thus,
a critical change that occurs during tumorigenesis is the
inability of the basal cells to properly differentiate. To
date, the histopathological characteristics of this cancer-
related alteration have been described in detail, but the
molecular pathways that mediate this change in vivo are
less well known.
To contrast and compare the genes and molecular
pathways that mediate these physiological and patholo-
gical states in patients, we microdissected normal squa-
mous epithelial basal cells, normal squamous epithelial
differentiated cells, and matched ESCC cells from twelve
ex vivo clinical samples and evaluated expression profiles
using microarrays. The primary aim of the study was to
compare the growth-related genes in normal basal cells
versus tumor cells in a search for new therapeutic tar-
gets, and hence, assess the feasibility of using a micro-
dissection based strategy to identify novel therapeutic
targets. As a first step towards this goal, we determined
the global patterns of gene expression and specific path-
ways associated with cell differentiation versus those
associated with tumorigenesis, and in parallel evaluated
the expression patterns of DNA damage and repair
related genes in ESCC since this tumor type exhibits
significant genomic instability [13-16]. Uniquely, the
current study uses microdissected normal basal epithe-
lium as a ‘growth filter’ to identify genes and pathways
specific to tumor growth.
Methods
Clinical tissue specimens
All cases and samples were obtained from subjects
residing in the Taihang mountain region of north cen-
tral China. This study was approved by the Institutional
Review Boards of the collaborating institutions (Single
Project Assurance Number# S-12118-01): Shanxi Cancer
Hospital and Institute, Taiyuan, Shanxi Province, China;
and the National Cancer Institute, Bethesda, MD, USA.
After obtaining informed consent, cases were inter-
viewed to obtain information on demographics, cancer
risk factors (eg, smoking, alcohol drinking and detailed
family history of cancer), and clinical information (Addi-
tional file 1: Table S3). None of the cases had prior ther-
apy. Using accepted inclusion criteria [17], twelve cases
having sufficient tumor and matched normal epithelium
were evaluated and selected by a pathologist (J.R.-C.).
Resected specimens from the 12 ESCC patients were
fresh frozen, blocked and stored at LN2 according to
standard practices [18] until assays could be performed.
Four matched ethanol-fixed paraffin-embedded blocks
from the above 12 cases, including both tumor and nor-
mal compartments were selected for protein validation
by immunohistochemistry (IHC).
Tissue processing
Immediately prior to use, the paired normal and tumor
samples were cut into 8 μm thick sections using a Leica
Cryostat, placed onto glass slides, and stored for less
than two weeks at -80°C. Before dissection, each section
was individually removed from storage and immediately
stained and dehydrated using an H&E protocol designed
for microdissection [19-21].
Laser capture microdissection
For each case, paired normal and tumor sections were
chosen and morphologically selected cell populations
were dissected by laser capture microdissection with the
PixCell IIe (Arcturus Engineering, Inc., Mountain View,
CA) [22], according to standard protocols [20]. After
H&E staining, the normal basal layer of the squamous
epithelium, consisting of 1-4 cells thick, including the
strata basale and parabasale immediately adjacent to the
basement membrane, was procured by LCM (Figure 1).
Next, the differentiated region of the epithelium, con-
sisting of stratum spinusm, stratum granulosum and
stratum lucidum cell layers was identified and retrieved
after LCM. Since the molecular profile comparison
between the regions was critical in this study, overlap-
ping of the two cellular subtypes was strictly avoided
during microdissection. Corresponding ESCC was
microdissected from matched tissue blocks in each case
using the same LCM protocol.
RNA isolation and assessment
The time from slide removal from the freezer to com-
pletion of LCM did not exceed 30 minutes. Following
LCM, RNA was isolated using the PicoPure RNA Isola-
tion kit (Arcturus Engineering, Inc. Mountain View,
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Page 2 of 16Figure 1 Histology of normal esophageal epithelium and ESCC before and after microdissection. A. Hematoxylin and eosin (H&E) staining
showing the three layers of normal esophageal epithelium. B. Normal esophageal epithelium after basal layer microdissection. C. Normal
esophageal epithelium after differentiated layer microdissection. D. ESCC clusters (Black circles) before microdissection. E. ESCC clusters (blank
areas) after microdissection. Magnification: A = 10×, B = 10×, C = 10×, D = 4×, E = 4×
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measured as previously described [19,21] using the Bioa-
nalyzer 2100 (Agilent Technologies, Inc., Palo Alto, CA)
and NanoDrop ND-1000 Spectrophotomer (NanoDrop
Technologies, Wilmington, DE), respectively.
RNA amplification, fragmentation, hybridization and
microarray
Total RNA was used as the template for amplification
because of bias reduction compared to using mRNA
template [23]. To ensure that all samples contained a
similar overall representation of transcriptome, 50 ng
of total RNA concentrations were used for each sam-
ple. Two rounds of linear amplification were per-
formed by combining reagents supplied in
MessageAmp™ II-Biotin Enhanced Single Round
aRNA Amplification Kit (Ambion, Catalog# AM1791,
Austin, TX) and MessageAmp™ II aRNA Amplifica-
tion Kit (Ambion, Catalog# AM1751), resulting in bio-
tin-labeled antisense cRNA [24]. Per sample,15 μgo f
biotin-labeled cRNA sample was fragmented and pro-
cessed for hybridization to Human Genome U133A 2.0
Genechips (Affymetrix Inc., Santa Clara, CA), accord-
ing to the Expression Kit User Manual http://www.
affymetrix.com/support/technical/manuals.affx). Arrays
were washed and stained using the Midi_euk2v3_450
protocol (V4). Fluorescent intensity emitted by the
labeled target was measured using a GeneChip Scanner
7 G (Affymetrix Inc.). The microarray gene expression
data can be accessed via GEO repository through the
following link: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE29001
Data analysis and statistics
(1) Microarray data quality control, preprocessing and gene
Filtering
Quality assessment of each microarray was done using
probe level model based quality statistics: normalized
unscaled standard error (NUSE) and relative log
expression (RLE). Arrays with their respective median
NUSE and RLE values exceeding the upper control
limits were considered as poor quality and excluded
from analysis. Only one of the 36 arrays did not pass
the quality control criteria (Additional file 1: Figure
S1). Robust Multi-Array (RMA) with quantile normali-
zation was completed for the 35 good quality arrays
using the Bioconductor suite of array analysis tools
running in R version 2.8.0 (R Development Core
Team, 2004). Probe sets showing minimal variation
across the 35 arrays were excluded from the analysis.
Probe sets were selected if their expression differed by
at least 1.5 fold from the median in at least 20% of the
arrays. Overall, 10,725 probe sets were retained and
used for analysis.
(2) Hierarchical clustering
Agglomerative hierarchical clustering was used to
inspect the global grouping of expression profiles from
tumors and normal tissues of the twelve patients. Both
specimens and genes were clustered with a 1-correlation
metric employing average linkage in R.
(3) Class comparison
Differentially expressed genes between subgroups of spe-
cimens were determined by multivariate permutation
test [25]. To control for the proportion of false positives,
the multivariate permutation test was used to provide a
less than 5% false positive rate with 95% confidence.
The test statistics used were the paired t-statistics for
each probe set. Although paired t-statistics were used,
the multivariate permutation test is non-parametric and
does not require the assumption of normal distributions
for gene expression measurements. The multivariate
permutation test was performed using BRB-Array Tools
version 3.8.0 software. Data of genes with > 2 fold
change in the class comparison were then visualized by
Principal Components Analysis (PCA). PCA maps were
generated by input of sub-type cell populations related
CEL files to Partek Genomics Suit (Partek, Inc., St.
Charles, MO).
(4) Pathway analysis
Genes identified by class comparison (fold change > 2)
as described above were used for network and gene
ontology analyses. Data were analyzed through the use
of Ingenuity Pathways Analysis (Ingenuity
® Systems,
http://www.ingenuity.com). Gene accession numbers
were imported into the Ingenuity Pathway Analysis sys-
tem and networks of the focus genes were algorithmi-
cally generated based on their connectivity. Briefly,
biochemical pathway analysis was performed by measur-
ing the ratio of the number of molecules in a given
pathway divided by the total number of molecules that
make up that pathway to generate networks in which
the differentially regulated genes are related to known
associations between genes or proteins, but independent
of established canonical pathways.
Immunohistochemistry
Immunohistochemical (IHC) staining of ethanol-fixed
and paraffin-embedded sections for protein expression
of four genes of interest (ODC1: ornithine decarboxylase
1; POSTN: periostin; ASPA: aspartoacylase; and, IMP3:
insulin-like growth factor 2 mRNA binding protein 3)
was performed using a standard IHC protocol as we
previously described [26]. IHC antibodies chosen repre-
sent available working antibodies in our laboratory, of
which four represented proteins in which gene expres-
sion was dysregulated in T epithelium. Antibodies used
included rabbit polyclonal anti-ODC1 primary antibody
(Sigma) at 1:200, rabbit polyclonal anti-POSTN primary
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primary antibody (Abcam) 1:300, and prediluted rabbit
polyclonal anti-IMP3 primary antibody (Abcam). Nega-
tive controls were established by replacing the primary
antibody with rabbit polyclonal IgG (Abcam).
Results
Technical parameters
A total of 36 microdissected samples from 12 patients
were generated. Normal basal epithelial cells, normal
differentiated epithelial cells, and tumor cells were pro-
cured from each patient specimen using 4000-8000 laser
shots (Figure 1). Total RNA from 35 of the 36 samples
was of sufficient quality for array analysis with a pre-
amplification mean RNA Integrity Number (RIN) of 6.6
(range 4.2 to 8.7; Additional file 1: Table S1, Additional
file 1: Figure S1).
Profile and pathway analysis
We first determined the global patterns of gene expres-
sion and specific pathways associated with cell differen-
tiation versus those associated with tumor growth and
evaluated the expression patterns of DNA damage and
repair related genes. This represents a cross-sectional
s t u d yt h a ti sag o o df i r s ts t e pi ng e n e r a t i n gab e t t e r
molecular understanding of ESCC.
Differentiation versus tumorigenesis
Initially, three sets of class comparisons were performed
for the filtered probe sets: T vs. NB (T/NB); T vs. ND
( T / N D ) ;a n dN Bv s .N D( N B / N D ) .O v e r a l l ,t h ed a t a
showed that gene expression in normal differentiated
cells was markedly different from both normal basal
cells and tumor; whereas, the tumor and normal basal
cells were more closely related. Specifically, for genes
with a > 2 fold change, T/ND (2990) and NB/ND (1916)
had a larger number of differentially expressed genes
than T/NB which showed only 575 changes (Figure 2A).
These data are reflected in the dendogram generated by
non-supervised clustering shown in Figure 3. We also
compared how the NB and ND cells clustered in com-
parison to tumor using PCA. Again, the ND cell sam-
ples were the most distinct based on location and
distance from the NB and T cell populations, consistent
with the number of differentially expressed genes (Fig-
ure 2B).
S i n c eal a r g en u m b e ro fd i f f e r e n t i a l l ye x p r e s s e dg e n e s
were initially identified among the four comparisons
(above three comparisons plus T/N which represents T
vs. NB + ND), the samples were secondarily filtered
according to the highest geometric mean fold change to
identify the set with the largest differences. A stringent
level corresponding to at least 4-fold alteration was used
to generate the top 10 up- and down-regulated genes for
each comparison (Table 1). As expected, several of the
top 10 up-regulated genes in ND (compared to T) were
related to formation of the epidermis (e.g. TGM3 and
SCEL) and were not altered in cancer. CRNN, also
known as squamous epithelial heat shock protein 53, was
highly up-regulated in ND (247.78 fold) and NB but not
T, suggesting that the processes of calcium binding [27],
mucosal/epithelial immune response and epidermal dif-
ferentiation [28] are not altered in cancer. In addition, a
comparison of expression profiles of stem-cell markers
CD44 (↑ 4.369 fold in NB/ND and ↑ 2.918 fold in T/ND)
and CD24 (↓ 3.789 fold in NB/ND and ↓ 14.275 fold in
T/ND) revealed that the NB and T showed a stem cell-
like high CD44 and low CD24 pattern relative to ND.
The T/N comparison identified 286 genes dysregulated
with at least a 4-fold change (Additional file 1: Figure
S2). Using IPA, CRISP databases we identified a subset of
10 tumor dysregulated genes (AURKA↑,C D C 2 ↑,
PDGFRA↓, PDGFA↑,I L 8 R B ↓,N P R 3 ↓,N R 3 C 2 ↓,O D C 1 ↑,
PRKCA↑,S O A T 1 ↑) where therapeutic agents exist
(MLN8054, flavopiridol, becaplermin, cilostazol, SB-
265610, nesiritide, fludrocortisones acetate, eflornithine,
L-threo-safingol, pactimibe; respectively) that act as inhi-
bitors or agonists to the tumor dysregulated genes and
are in clinical use or trial for other diseases. Moreover,
twelve unique cancer-associated genes (IGF2BP3↑, HLF↓,
SLC6A1↑,I L 1 R 2 ↓,D N A S E 1 L ↓,A S P A ↓,E D N 3 ↓,
PDCD4↓, COL14A1↓,R G S 5 ↓, DEPDC6↓ and PAX5↓)
were discovered using the dissected cell comparison of
T/NB as they did not overlap with the genes identified in
t h et u m o rv e r s u sw h o l en o r m a l( N B+N D )c o m p a r i s o n ,
demonstrating the technical value of the microdissection
strategy employed in the study.
We next compared and contrasted overall NB cell
transcript levels versus that of ND and T cells to assess
the directionality of gene expression changes that occur
in cell differentiation versus tumorigenesis. After nor-
malization and filtering of the data sets, two-way hier-
archical cluster analysis identified a specific gene
expression pattern associated with each cell population
(Figure 3). Notably, the proportion of down-regulated
genes was larger than up-regulated genes in tumor as
compared to NB (61%). Conversely, the proportion of
up-regulated genes was more (73%) than down-regu-
lated genes in the differentiated layer as compared to
the basal layer. These data indicate that normal differen-
tiation and tumorigenesis take opposite paths with
respect to the relative number of up- and down-regu-
lated genes as they develop from NB cells.
To further understand the expression patterns asso-
ciated with each cell population, we used the computa-
tional tool Ingenuity Pathway Analysis (IPA) to investigate
biological pathways to provide a more refined functional
classification of genes (Additional file 1: Table S2). First,
analysis of expression profiles in the cell populations in
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Page 5 of 16Figure 2 Class comparison and principal components analysis (PCA) among the cell populations. A. Class comparisons show the
numbers of differentially expressed genes with > 2 fold change on each comparison. B. PCA mapping for the microarray data. The gene
expression data (> 2 fold change) for each cell population are represented by different colors: normal basal cell (NB) gene expression = red;
normal differential cell (ND) gene expression = blue; and tumor cell (T) gene expression = green.
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was performed (Table 2). In general, the NB/ND compari-
son was involved in more pathways with a significant
increase relative to other comparisons (Table 2). With
respect to Diseases and Disorders of Top Biological Func-
tions, NB/ND and T/ND were ranked in the same order
with T/NB showing a unique pattern (Additional file 1:
Table S2). However, instead of the Genetic Disorder path-
way, Reproductive System Disease was identified as the
third most related in T/NB. Although each of the compar-
isons was associated with cancer, they differed in the most
significant sub-classification of cancer related genes: T/ND
= colorectal cancer (e.g. BRAF, MET); T/NB = increased
in cancer (e.g. FBXW7, PDGFA); and T/N = increased in
cancer, and identified additional genes that were not pre-
sent in the other comparisons (e.g. MECOM, BRCA1).
Finally, biochemical pathway analysis revealed the top net-
work for each comparison (Fig u r e4 ) .N o t a b l y ,t h eI g G
network appeared on all three tumorigenesis related com-
parisons (T/N, T/NB, T/ND), the PDGF-BB and FSH net-
works were identified in the T/NB comparison, and FSH
was the top network in the NB/ND comparison. In all
three comparisons to T (T/N, T/NB, T/ND), ISG15 asso-
ciated with the FGF Signaling pathway was the most sig-
nificantly up-regulated gene in the IgG network, and was
one of the top 10 up-regulated genes of the T/NB compar-
ison (Table 1).
DNA damage and repair
BRCA1 was up-regulated in T compared to ND (7.08
fold) and N overall (NB + ND) (3.22 fold) and up-regu-
lated in NB compared to ND (3.7 fold); however,
BRCA1 was not differentially expressed in the T/NB
comparison (Table 3). This finding was corroborated by
pathway analysis as the top canonical pathway in both
t h eT / N Da n dN B / N Dc o m p a r i s o n sw a st h eR o l eo f
BRCA1 in DNA Damage and Response pathway, but
not in the T/NB comparison (Table 2).
Similarly, other DNA damage pathways including
G2M DNA Damage Checkpoint Regulation and p53 Sig-
naling showed a similar pattern as the Role of BRCA1 in
DNA Damage and Response pathway; they were up-
regulated in T and NB compared to ND, with no signifi-
cant difference in the T/NB comparison. These findings
suggest that DNA repair pathways generally, and the
Figure 3 Two-way hierarachical clustering on NB vs. ND and T vs. NB. The differentially expressed genes with fold change > 4 in the NB vs.
ND and T vs. NB comparisons were applied in this analysis. Each row represents a gene and each column corresponds to a sample. Expression
of each gene was median-centered across all specimens for that gene. Shades of red represent degrees of increasing expression, and shades of
green represent degrees of decreasing expression.
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both normal basal cells and tumor relative to differen-
tiated cells, and might prevent or correct errors during
cell division in normal cells and as a compensatory
response to DNA damage in tumor cells.
Therapeutic target identification
Due to the limited efficacy of current treatment regi-
mens for ESCC, the identification of potential new ther-
apeutic targets was the primary goal of the study. As a
unique approach, we utilized microdissected normal
Table 1 Top 10 significant transcripts of each comparison
Comparison Genes Fold-change up-regulated Genes Fold-change down-regulated
T vs. N* MMP1 17.234 CRNN -127.008
SPP1 16.244 CLCA4 -48.772
LHX2 16.178 KRT13 -48.77
MAGEA3 13.484 MAL -47.356
POSTN 12.907 SPRR3 -45.444
CXCL11 12.892 TGM3 -43.083
INHBA 12.846 KRT4 -36.124
COL11A1 12.773 RHCG -32.492
KRT17 12.284 SPINK5 -25.795
HOXA9 11.241 CYP4B1 -22.326
T vs. NB KRT17 19.58 CRNN -76.12
SPP1 17.715 KRT13 -43.49
MMP1 17.433 TFAP2B -36.57
LHX2 15.462 MAL -34.49
MAGEA3 14.996 KRT4 -34.27
INHBA 13.668 SPRR3 -33.57
COL11A1 13.558 CYP4B1 -31.25
POSTN 10.788 CLCA4 -29.347
HOXA9 9.405 RHCG -22.791
ISG15 9.148 SPINK5 -18.506
T vs. ND MMP1 21.074 CRNN -247.775
CXCL11 20.169 TGM3 -130.782
LHX2 18.786 MAL -80.503
POSTN 15.136 SCEL -67.596
MAGEA3 14.998 SPRR3 -64.667
ECT2 14.384 SYNPO2L -63.086
TOP2A 14.229 KRT13 -58.246
AURKA 13.738 SLURP1 -56.244
SPP1 13.712 UPK1A -55.326
PTHLH 12.817 FLG -52.983
NB vs. ND TFAP2B 10.432 SYNPO2L -20.626
CXCL14 10.196 MXD1 -14.761
SERPINE2 6.592 FLG -13.662
NCAPG 5.708 ANXA9 -12.746
TOP2A 5.676 EREG -12.346
PTHLH 5.236 PRSS3 -12.131
NDC80 5.223 DKK1 -11.945
RRM2 5.199 ECM1 -11.893
PPAT 4.928 MUC1 -11.814
CH25H 4.561 ZNF365 -11.774
*N=N B+M D
Yan et al. BMC Research Notes 2012, 5:73
http://www.biomedcentral.com/1756-0500/5/73
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tor for tumor (T) - in other words, a normal cell popu-
lation with a relatively high growth rate. Direct
comparison of these cells to rapidly growing tumor cells
was performed as a biological filter to de-emphasize
identification of genes associated with regular growth
processes and favor identification of genes or pathways
that are more closely related to tumorigenesis per se.
Two pathways and twelve genes stood out as putative
therapeutic targets. The PDGF signaling pathway was
the most significant cancer associated pathway in the T/
NB comparison (Figure 4B, Table 2), and the EGF sig-
naling pathway was also dysregulated. Both PDGF and
EGF signaling pathways have been targeted by tyrosine
kinase inhibitors in some cancers, but not yet in ESCC.
For example, PDGFA and PDGFRA of the PDGF signal-
ing pathway (Table 4) are targeted by approved drugs
for other cancers and potentially could be exploited for
use in ESCC. Twelve differentially expressed genes were
uniquely identified in the T/NB comparison (IGF2BP3↑,
HLF↓,S L C 6 A 1 ↑,I L 1 R 2 ↓,D N A S E 1 L ↓,A S P A ↓,E D N 3 ↓,
PDCD4↓, COL14A1↓,R G S 5 ↓, DEPDC6↓,P A X 5 ↓)w i t h
at least a 4-fold change (Additional file 1: Figure S2). In
addition to genes identified in the T/NB comparison,
two genes were noted to link the identified networks
together. STAT1 interacts between the PDGF-BB and
FSH pathways, whereas TNFAIP3 interfaces with FSH
and IgG. Finally, ISG15 was specific to T in all compari-
sons and was one of the top 10 genes upregulated in T
in compared to NB (Table 1), indicating that ISG15 is
worth investigating further as a putative therapeutic
target.
Protein expression validation
Intra-section protein expression of four selected candi-
date genes was compared between tumor and adjacent
normal cells in 4 of the 12 ESCC cases, allowing assess-
ment of their protein expression directly from the same
slide and excluding differences attributed to the staining
process. POSTN, the most overexpressed gene in the T/
N comparison (Table 1), stained stroma (all 4 cases)
around the tumor cells but not near normal cells.
Tumor cells and normal cells were not stained (Figure
5A). Out of the 10 genes identified with available thera-
peutic agents, ODC1 is the only gene currently being
investigated in esophageal cancer. ODC1 was positive in
the cytoplasm of the tumor cells (3 from 4 cases).
Tumor stroma and the normal basal layer showed weak
staining (Figure 5B). ASPA was one of the twelve differ-
entially expressed genes identified uniquely in the T/NB
comparison and showed strong staining in the normal
epithelium and light staining in the tumor area (3 from
4 cases) (Figure 5C). In the case of IMP3/IGF2BP3,
staining was only detected in the smooth muscle cells
across tumor and adjacent normal regions, but not in
tumor, normal cells, or stroma (data not shown). This
result did not validate the mRNA distribution pattern.
Discussion
Laser dissection instrumentation continues to evolve
and now facilitates the procurement of essentially pure
populations of cells for study [19,22,29]. In parallel, the
methods for analyzing small numbers of dissected cells
are becoming increasingly robust and have been used
successfully by many research groups, adding to the
Table 2 Cancer associated pathway analysis.
Pathway T vs. N T vs. NB T vs. ND NB vs. ND
Role of BRCA1 in DNA Damage Response 6.99E-07↑ 4.75E-01 3.05E-09↑ 2.09E-06↑
C2M DNA Damage Checkpoint Regulation 1.03E-03↑ 3.53E-01 7.46E-04↑ 8.07E-06↑
p53 Signaling 1.50E-02 5.85E-02 1.77E-04↑ 5.11E-06↑
G1/S Checkpoint Regulation 2.94E-02 - 4.22E-02 1.47E-03↑
PPAR signaling 6.41E-02 1.33E-01 1.78E-02 1.03E-03↓
EGF Signaling - 1.49E-02 3.94E-01 1.49E-01
p38 MARK Signaling 1.77E-01 1.69E-01 1.74E-01 1.01E-01
PDGF Signaling 2.11E-01 7.20E-03↑ 8.31E-02 7.56E-02
NF-kB Signaling 2.13E-01 6.61E-02 3.03E-01 3.35E-02
ERK/MAPK Signaling - 3.22E-01 6.64E-02 5.20E-01
VEGF Signaling - - 3.15E-01 1.71E-01
IGF-1 Signaling - - 3.83E-01 1.28E-01
TGF-b Signaling - - 5.00E-01 5.09E-01
cAMP-mediated Signaling - - - 4.21E-01
FGF Signaling - 4.70E-01 - 3.62E-01
p-value comparison on cancer associated pathway
- represent no p value showed on the IPA Canonical pathways analysis.
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methods [16,30,31]. For example, our group has devel-
oped methodologies for and demonstrated that we are
able to obtain highly reproducible, statistically valid gene
expression array and quantitative qRT-PCR measure-
ments using microdissected specimens [19,21,24]. In the
present study, we examined expression profiles in eso-
phageal cancer specimens using Affymetrix expression
arrays and the latest generation LCM technology to
study ESCC in ex vivo patient samples. Because of the
limited efficacy of current ESCC treatment regimes, the
primary goal was to compare the expression patterns of
growth-related genes in normal basal cells versus tumor
cells in a search for potential therapeutic targets. As a
step towards identifying therapeutic targets, we first
looked at global patterns of gene expression and specific
pathways associated with cell differentiation versus
those associated with tumorigenesis and expression pat-
terns of DNA damage and repair related genes. Overall,
profile and pathway analysis data of cell type (T, NB,
ND) comparisons revealed potential therapeutic pathway
targets and individual gene targets (e.g. ISG15, IMP3,
and EIF2AK2). Using the dissected T/NB cell compari-
son, the PDGF pathway and 12 genes unique to this
comparison were identified as putative therapeutic tar-
gets for ESCC. In addition, 10 potential ESCC gene-
drug pairs were identified.
Differentiation versus tumorigenesis
To understand patterns of gene expression associated
with cell differentiation versus tumorigenesis, we com-
pared and contrasted the NB, ND, and T cell profiles.
The class comparisons and PCA both revealed that ND
cell samples were the most distinct based on location
Figure 4 Top network comparisons. A. N vs. T - Organ Development and Nutrition Disease network. B. NB vs. T - Molecular Transport and
Small Molecule Biochemistry network. C. ND vs. T - Cancer and Cellular Growth and Proliferation network. D. NB vs. ND - Organ Development,
Nutritional Disease network. Maps were created by Ingenuity Pathway Analysis software. Red icons depict genes up-regulated; green icons
depict down-regulated genes. Color intensity represents the degree of dysregulation, for example, the dark red indicates more overexpression
than light red. Lines show interactions between proteins.
Yan et al. BMC Research Notes 2012, 5:73
http://www.biomedcentral.com/1756-0500/5/73
Page 10 of 16and distance from the basal and tumor cell populations.
Moreover, the normal differentiation process (compar-
ing NB to ND) appears to be mediated primarily by up-
regulation of genes since 73% of differentially expressed
transcripts were increased over basal cell levels. In con-
trast, the tumor cells showed primarily down-regulation
(61%) of expressed transcripts compared to the NB cells,
with the small percentage of up-regulated mRNAs being
associated with cell growth, a pattern similar to what we
have observed in other tumor types [24], and may be
partially resultant from their aberrant methylation
[32,33].
Regarding normal differentiation, the IPA pathway
analysis showed that hypoxia signaling was dysregulated
in NB/ND (p-value: 1.36E-03), without showing signifi-
cant difference in the other comparisons. In response to
hypoxia, activation of hypoxia-inducible factor 1 (HIF-1)
occurs, and activated HIF-1 mediates cell growth, prolif-
eration and cell death through interaction with the p53
and MDM2 pathways [34]. The NF-B signaling
Table 3 Role of BRAC1 in DNA Damage Repair gene expression in T vs. ND comparison
Symbol Entrez Gene Name Fold change
ATR ataxia telangiectasia and Rad3 related 4.374
BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 -2.319
BLM Bloom syndrome, RecQ helicase-like 2.927
BRCA1 breast cancer 1, early onset 7.08
CHEK1 CHK1 checkpoint homolog (S. pombe) 5.918
CHEK2 CHK2 checkpoint homolog (S. pombe) 2.201
E2F1 E2F transcription factor 1 2.425
E2F3 E2F transcription factor 3 5.759
E2F6 E2F transcription factor 6 2.967
FANCA Fanconi anemia, complementation group A 2.319
FANCE Fanconi anemia, complementation group E 2.135
FANCG Fanconi anemia, complementation group G 2.916
HLTF helicase-like transcription factor 6.376
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 2.589
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 2.049
MSH6 mutS homolog 6 (E. coli) 4.538
RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 4.533
RBBP8 retinoblastoma binding protein 8 2.143
RBL1 retinoblastoma-like 1 (p107) 6.574
RFC3 replication factor C (activator 1) 3, 38 kDa 4.67
RFC4 replication factor C (activator 1) 4, 37 kDa 11.105
RFC5 replication factor C (activator 1) 5, 36.5 kDa 5.366
RPA1 replication protein A1, 70 kDa 2.605
SLC19A1 solute carrier family 19 (folate transporter), member 1 2.058
STAT1 signal transducer and activator of transcription 1, 91 kDa 4.826
Table 4 PDGF Signaling Pathway gene expression in T vs. NB comparison
Symbol Entrez Gene Name Fold change
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 2.099
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog -5.056
PDGFA platelet-derived growth factor alpha polypeptide 2.138
PDGFRA platelet-derived growth factor receptor, alpha polypeptide -2.62
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) -2.513
PRKCA protein kinase C, alpha 2.192
STAT1 signal transducer and activator of transcription 1, 91 kDa 2.315
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Page 11 of 16Figure 5 Protein expression assessments of POSTN, ODC1, and ASPA. Immunohistochemical staining of POSTN (A), ODC1 (B), and ASPA (C)
are shown, with rabbit IgG (D) as the negative control. The left and middle panels for each represent tumor area at the magnification of 40×
and 10×. The right panel for each represents the tumor adjacent normal area at a magnification of 10×
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son. NF-B is a protein complex that controls the tran-
scription of DNA (Table 2) and as such regulates cell
proliferation and cell survival [35]. Finally, CXCL14 was
one of the top 10 up-regulated genes from the NB/ND
comparison. CXCL14 is a new CXC chemokine with
unknown function and receptor selectivity and is consti-
tutively expressed in normal tissues and binds to its
receptor on epithelial cells to enhance proliferation,
migration, and invasion [36].
The individual gene data indicate that, as anticipated,
esophageal basal cells develop into tumors through up-
regulation of oncogenes and down-regulation of tumor
suppressor genes. For example, transcripts for suppres-
sors TFAP2B AP-2 a/b,H L F( ↓7.951 fold) and EDN3
(↓5.932 fold) were decreased in tumor cells compared to
basal cells (Table 1). TFAP2B is an AP-2 transcription
factor that promotes normal cell apoptosis. And, a role
for the AP-2 gene family in the control of cell growth
and differentiation has been observed in breast cancer
[37]. AP-2 a/b is another member of the AP-2 gene
family and has also been implicated as a breast cancer
suppressor gene [38]. In contrast, the oncogene
IGF2BP1-3 (IMP3, ↑8.793 fold) was highly over
expressed in tumor relative to NB. IMP3 normally regu-
lates mRNA transport, translation, and turnover by
binding the coding regions of target mRNAs such as
IGF2 [39]. However, IMP3 expression has been corre-
lated with increased tumor aggressiveness and reduced
overall survival in pituitary tumors [40]. Our data sug-
gest that this may also the case in ESCC and that IMP3
may be a putative therapeutic target for ESCC.
DNA damage and repair
ESCCs exhibit extensive genomic instability, a feature
that underlies their rapid growth and aggressive clinical
course. As expected, we observed widespread dysregula-
tion of genes involved in DNA repair and genomic sta-
bility in the ESCC samples with BRCA1 being one of
the most over-expressed genes in tumors. Interestingly
the Role of BRCA1 in DNA Damage and Response
pathway was increased in both NB cells and tumor com-
pared to ND cells. Moreover, other DNA damage path-
ways, including G2M DNA Damage Checkpoint
Regulation and p53 Signaling, showed a similar expres-
sion pattern (Table 2).
Overall, the data indicate that important DNA repair
and surveillance pathways are activated in vivo during
both normal and pathological growth, an observation
that will need to be factored into strategies that look to
exploit these targets for therapeutic purposes. As a
tumor suppressor gene, BRCA1 repairs damaged DNA
and destroys cells when DNA cannot be repaired [41].
The G2M DNA Damage Checkpoint Regulation
pathway acts to recognize damaged DNA and stop cell
cycle progression at the G2/M transition, and defective
G2/M checkpoints may increase cytotoxicity of che-
motherapy [42]. BRCA1 is also essential in activating
the Chk1 kinase that regulates DNA damage-induced
G2/M transition [43]. The p53 Signaling pathway works
to block cell division in response to DNA damage [44],
partially through the G2/M checkpoint regulation [45].
The data suggest that DNA damage and repair pathways
may not be a fruitful source of therapeutic targets.
Therapeutic targets
We utilized a T/NB comparison to identify pathways
and genes that could be putative therapeutic targets. In
other words, we contrasted the expression profile of a
normal dividing cell population against its counterpart
transformed cell population in a search for growth-
related genes that are unique to cancer and not part of
the standard cell growth machinery per se, as opposed
to comparing full-thickness normal epithelium that
would necessarily include a high proportion of non-
dividing differentiated cells [46]. As a general matter,
this is an issue of concern for many studies aimed at
uncovering dysregulated genes in tumors, especially
common epithelial neoplasms where the majority of
normal epithelium is quiescent. In ESCC however, the
ability to selectively procure the self-renewing basal
stem cell compartment allowed us to directly compare
gene expression profiles between normally dividing cells
and tumors. With regards to the concern that there is
more than one cell type in the NB, we are working to
adapt a new technology to esophageal specimens called
expression microdissection (xMD) that facilitates pro-
curement of molecularly-targeted sub-populations
within a given tissue compartment [47,48].
Using the T/NB filter, the major cancer associated
pathway in the comparison was overexpression of PDGF
Signaling (Figure 4B, Table 2). Biologically, tumor
growth can be promoted by PDGF via autocrine stimu-
lation of malignant cells, by over-expression or over-
activation of PDGF receptors, or by PDGF stimulation
of angiogenesis within the tumor [49]. Known PDGF
inhibitors such as imatinib mesylate have been used for
several cancers and achieved clinical efficacy [49-51].
Our present data suggest that inhibition of the PDGF
pathway may also be beneficial in treating ESCC.
In addition to potential therapeutic pathway targets,
individual gene targets were also investigated. ISG15
was the most overexpressed gene in the IgG network
(Figure 4) and one of the top 10 overexpressed genes in
the NB/T comparison (Table 1). ISG15 is associated
with the FGF Signaling pathway and involved in protein
metabolism and modification and has been associated at
the protein and transcriptomic levels in oral cancer
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Page 13 of 16[52-54] and was once associated with ESCC [55], sug-
gesting that inhibition of ISG15 may be beneficial in
treatment. Overall, 12 genes were identified as being
specific to the T/NB comparison and represent unique
therapeutic targets. As evidenced by the clinical success
of imatinib, gefitinib, and erlotinib, kinase family gene
targets may be a useful place to begin investigating new
therapeutic agents. The data identified several kinases
that are up-regulated in tumor cells, including; MET,
PFTK1, BUB1, CKS1B, EIF2AK2, and NEK2. Interest-
ingly, EIF2AK2 regulates TP53; TP53 regulates BUB1
and NEK2; and NEK2 regulates BRCA1. Therefore,
potentially targeting upstream at EIF2AK2 may have a
good chance of therapeutic efficacy in ESCC.
We also identified the following sets of gene-drug
pairs, i.e., therapeutic agents that act as appropriate inhi-
bitors or agonists with identified tumor dysregulated
genes: 1) AURKA, targeted by MLN8054, inhibitor; 2)
CDC2, targeted by flavopiridol, inhibitor; 3) PDGFRA,
targeted by becaplermin, agonist; 4) PDGFA, targeted by
cilostazol, inhibitor; 5) IL8RB, targeted by SB-265610,
agonist; 6) NPR3, targeted by nesiritide, agonist; 7)
NR3C2, targeted by fludrocortisones acetate, agonist; 8)
ODC1, targeted by eflornithine, inhibitor; 9) PRKCA,
targeted by L-threo-safingol, inhibitor; and 10) SOAT1,
targeted by pactimibe, inhibitor. Of these 10 genes and
therapeutic agent combinations, only one is currently
being investigated in esophageal cancer: ODC1/eflor-
nithine, of which a phase II clinical trial (NCT00003076)
was recently completed although study results have not
been posted yet. However, targeting of ODC1 has been
successfully used in a combination therapy trial where a
low dose of chemopreventive drugs difluoromethylor-
nithine (DFMO; targeting ODC1) plus sulindac has
shown notable efficacy in preventing colorectal adenoma
recurrence [56] with few side effects.
From the above potential therapeutic targets, four genes
were selected for further protein level assessment by IHC.
ODC1 showed a consistent distribution pattern at both
the mRNA and protein level. ASPA exhibited strong stain-
ing in the normal epithelium compared to tumor as
expected, but did not show increased staining in the NB
compared to ND. The 2-fold mRNA overexpression of
ASPA may be insufficient to be reflected at the protein
level. Since POSTN was reported as an extracellular pro-
tein [57], the staining of the stroma around the tumor
implied that the tumor cells secrete POSTN to tumor
stroma. This observation is consistent with the array data
as tumors expressed over 10-fold more POSTN than nor-
mal esophageal epithelium. Similar immunostaining of
POSTN was also reported by Kwon et al. [58] and there
are recent reports of the role of POSTN in pancreatic,
ovarian and gastric cancer, and potential agents are noted
to influence its expression [59]. Overall, the mRNA
expression pattern of three of the four selected genes was
validated at the protein level.
Conclusions
The current study used a unique tissue microdissection
strategy and microarrays to measure gene expression
profiles associated with cell differentiation versus tumor-
igenesis in twelve cases of patient-matched normal basal
squamous epithelial cells (NB), normal differentiated
squamous epithelium (ND), and squamous cell cancer.
We observed that ND expression patterns were mark-
edly different from NB and tumor; whereas, tumor and
NB were more closely related. Tumors showed a general
decrease in differentially expressed genes relative to NB
as opposed to ND that exhibited the opposite trend. In
addition, the FSH and IgG networks were most highly
dysregulated in normal differentiation and tumorigen-
esis. DNA repair pathways were generally elevated in
NB and tumor relative to ND indicating involvement in
both normal and pathological growth. Moreover, PDGF
signaling pathway and 12 individual genes unique to the
tumor/NB comparison were identified as therapeutic
targets. We further examined the protein expression
level and the distribution patterns of four genes: ODC1,
POSTN, ASPA and IGF2BP3, and three (ODC1,
POSTN, ASPA) were altered at the protein level. The
analysis of microdissected normal and pathological cell
populations from ex vivo clinical samples has revealed
new insights into the genes and molecular pathways
that mediate ESCC development, demonstrated the fea-
sibility of using a microdissection-based strategy to iden-
tify novel therapeutic targets, and may be an effective
strategy for studying various cancer types more gener-
ally. Certainly however, further validation of the identi-
fied genes and pathways is needed to confirm the
present findings in a larger cohort of patients before
conclusions can be drawn about therapeutic targets, and
t h ei s s u eo ft u m o rh e t e r o g e n e i t yw i l la l s on e e dt ob e
explored for candidate differentially expressed genes.
Additional material
Additional file 1: Table S1. Sample microdissection and RNA
assessment. Table S2. Pathway analysis summary. Table S3. Clinical
annotation of the twelve ESCC cases studied. Figure S1. Quality control
assessment of each array using normalized unscaled standard error
(NUSE) and relative log expression (RLE). × axis represents individual
cases; Y axis represents NUSE median and RLE median separately. Figure
S2. Venn diagram across NB/T, ND/T and N/T. Input data are those
differential expressed genes from each comparison with ≥ 4-fold change.
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